Inhibition of pentagastrin-induced pressor response in conscious rats by the CCK-B receptor antagonist CI-988 and chlordiazepoxide

Regulatory Peptides

Volumn 61, Issue 1, 1996, Pages 71-76

  Webb, J K ^a   Rupniak, N M J ^a   Boyce, S ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

Animal model; Anxiety; Blood pressure; Panic attack

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORDIAZEPOXIDE; CHOLECYSTOKININ B RECEPTOR; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; PENTAGASTRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PANIC; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0030071089     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-0115(95)00140-9     Document Type: Article

References (27)

1. Abelson, J.L. and Nesse, R.M., Cholecystokinin-4 and panic. Arch. Gen. Psychiat., 47 (1990) 395.
2. Abelson, J.L. and Nesse, R.M., Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. Biol. Psychiat., 36 (1994) 73-83.
3. Braestrup, C. and Neilsen, M., Neurotransmitters and CNS disease: anxiety. Lancet, ii (1982) 1030-1034.
4. Costall, B., Domeney, A.M., Hughes, J., Kelly, M.E., Naylor, R.J. and Woodruff, G.N., Anxiolytic effects of CCKB antagonists. Neuropeptides, 19 (1991) 65-73.
5. B antagonists in animal screens for anxiolytic drugs. Psychopharmacology, 121 (1995) 109-117.
6. De Montigny, C., Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiat., 46 (1989) 511-517.
7. Dorow, R., FG7142 and its anxiety-inducing effects in humans. Br. J. Clin. Pharmacol., 23 (1987) 781-782.
8. Dorow, R., Horowski, R., Paschelle, G., Amin, M. and Braestrup, C., Severe anxiety induced by FG7142, a β-carboline ligand for benzodiazepine receptors. Lancet, ii (1983) 98-99.
9. Ervin, F.R., Palmour, R.M. and Bradwejn, J., A new primate model for panic disorders. Biol. Psychiat., 29 (1991) 430S.
10. Hibbert, G.A., Ideational components of anxiety: their origin and content. Br. J. Psychiat., 144 (1984) 618-624.
11. Hughes, J., Boden, P., Costall, B., Domeney, A., Kelly, E., Horwell, D., Hunter, J.C., Pinnock, R.D. and Woodruff, G.N., Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci USA, 87 (1990) 6728-6732.
12. Liebowitz, M.R., Gorman, J.M., Fyer, A.J., Levitt, M., Dillon, D., Levy, G., Appleby, I.L., Anderson, S., Palij, M., Davies, S.O. and Klein, D.F., Lactate provocation of panic attacks: II Biochemical and physiological findings. Arch. Gen. Psychiat., 42 (1985) 709-719.
13. Lotti, V.J. and Chang, R.S.L., A new and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur. J. Pharmacol., 162 (1989) 273-278.
14. Meltzer, L., Christoffersen, C.L., Serpa, K.A. and Razmpour, A., Comparison of the effects of the cholecystokinin-B receptor antagonist, PD134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area. Synapse, 13 (1992) 117-122.
15. Pagani, F.D., Taveira da Silva, A.M., Hamosh, P., Garvey, T.Q. and Gilles, R.A., Respiratory and cardiovascular effects of intraventricular cholecystokinin. Eur. J. Pharmacol., 78 (1982) 128-132.
16. Palmour, R.M., Ervin, F.R., Bradwejn, J. and Haubert, J.J., Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCK-B antagonist LY262691. Soc. Neurosci. Abstr., 17 (1991) 637.
17. B receptor antagonists by ex vivo binding. Eur. J. Pharmacol., 253 (1994) 237-244.
18. B antagonist, on the punished responding of squirrel monkeys. Neuropeptides, 19 (1991) 75-78.
19. Pratt, J.A., Laurie, D.J. and McCulloch, J., The effects of FG7142 upon local cerebral glucose utilisation suggest overlap between limbic structures important in anxiety and convulsions. Brain Res., 475 (1988) 218-231.
20. Rasmussen, K., Czachura, J.F., Stockton, M.E. and Howbert, J.J., Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther., 264 (1992) 480-488.
21. B antagonist LY262691 decreases midbrain dopamine unit activity. Eur. J. Pharmacol., 209 (1991) 135-138.
22. Rossier, J., Dodd, R., Felblum, S., Valin, A., Prado De Carvalho, L., Potier, P. and Naquet, R., Methylamide β-carboline (FG7142) an anxiogenic benzodiazepine antagonist, is also a proconvulsant. Lancet, I (1983) 77-78.
23. Rupniak, N.M.J., Schaffer, L., Siegl, P. and Iversen, S.D., Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys. Neuropeptides, 25 (1993) 115-119.
24. SCRIP, Progress with peptide antagonists. SCRIP (1949) 20.
25. B receptor in anxiety. Proc. Natl. Acad. Sci. USA, 88 (1991) 1130-1133.
26. B receptor antagonist. Br. J. Pharmacol., 104 (1991) 239-245.
27. Traub, M., Lines, C. and Ambrose, J., CCK and anxiety in normal volunteers. Br. J. Clin. Pharmacol., 36 (1993) 504P.